Risk factor
Strong trading liquidity
Profitability factor
Excellent dividends
About
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is 'cheap' on P/E, overvalued on EV/EBITDA
Target Price
The average target price of BAX is 24 and suggests 27% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell